AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24916038
Drug: Adoptive immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive immunotherapy using ex vivo-expanded cytokine-induced killer (CIK) cells, administered intravenously 10 times, every week for 5 weeks and then every other week for 10 weeks.
Trial: 24916038
Drug: Adoptive immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive immunotherapy using ex vivo-expanded cytokine-induced killer (CIK) cells.
Trial: 24916770
Drug: Navitoclax 325
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax 325 mg co-administered with gemcitabine 1,000 mg/m(2) (21-day dosing schedule)
Trial: 24916770
Drug: Navitoclax doses
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax doses escalated from 150 to 425 mg
Trial: 24916770
Drug: Navitoclax 325
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax 325 mg with gemcitabine 1,000 mg/m(2)
Trial: 24916908
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy preparation through TIPS trial
Trial: 24917966
Drug: Antibiotics (H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (H. pylori-positive patients)
Trial: 24917966
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg b.d. for 7 days, followed by 40 mg o.d. for 8 weeks (all patients)
Trial: 24918167
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment in patients with SLCO1B1 genotype rs4149056T>C
Trial: 24919462
Drug: Dacetuzumab (SGN-40),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacetuzumab (SGN-40), 8 mg/kg/week, administered intravenously for up to 12 cycles
Trial: 24920166
Drug: Clock Drawing
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clock Drawing Test (CDT) administered at baseline and annually thereafter
Trial: 24920586
Drug: Single-agent ixazomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent ixazomib 0.24 to 2.23 mg/m(2) (days 1, 4, 8, 11; 21-day cycles)
Trial: 24920586
Drug: Single-agent ixazomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent ixazomib 0.24 to 2.23 mg/m(2)
Trial: 24920921
Drug: Concurrent thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent thoracic radiotherapy and erlotinib
Trial: 24923356
Drug: Osteoprotegerin (OPG)
RxNorm normalized name: Osteoprotegerin recombinant
DrugBank: AMGN-0007 (DB06511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoprotegerin (OPG) levels in Turner syndrome on antihypertensive medication
Trial: 24923792
Drug: DMPA users
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA users with calcium intake ≥ 1 g/day
Trial: 24924750
Drug: Blank solutions
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank solutions with mineral oil
Trial: 24925526
Drug: Fluconazole (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (0.4 µmol·min(-1)·l(-1))
Trial: 24925526
Drug: N(G)-monomethyl-L-arginine (L-NMMA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-monomethyl-L-arginine (L-NMMA, 8 µmol/min)
Trial: 24926953
Drug: Metreleptin (0.06-0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (0.06-0.24 mg/kg/d) administered for 24 months
Trial: 24927856
Drug: Otlertuzumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otlertuzumab (10 or 20 mg/kg) in combination with rituximab (375 mg/m(2)) and bendamustine (90 mg/m(2)); administered IV on days 1 and 15 for up to six 28-day cycles.
Trial: 24927856
Drug: Otlertuzumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otlertuzumab (10 or 20 mg/kg) in combination with rituximab and bendamustine;
Trial: 24927856
Drug: Otlertuzumab in
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Otlertuzumab in combination with rituximab and bendamustine;
Trial: 24928772
Drug: carlumab +
RxNorm normalized name: Carlumab
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carlumab + chemotherapy (all arms)
Trial: 24929258
Drug: Normal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Normal progesterone levels (≤4.77 nmol/L or ≤1.5 ng/mL)
Trial: 24929258
Drug: Elevated progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Elevated progesterone levels (>4.77 nmol/L or >1.5 ng/mL)
Trial: 24929484
Drug: Volatile organic
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile organic compounds (VOCs) in bile analyzed using selected ion flow tube mass spectrometry (SIFT-MS).
Trial: 24932181
Drug: Montelukast monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast monotherapy
Trial: 24932181
Drug: Montelukast add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast add-on therapy
Trial: 24934522
Drug: Elevated brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated brain natriuretic peptide (>21 pg/mL) and low Child Health Questionnaire physical summary score (<44)
Trial: 24934522
Drug: Arrhythmia requiring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arrhythmia requiring treatment
Trial: 24935348
Drug: Fractional sodium
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional sodium excretion
Trial: 24939214
Drug: Famitinib 25
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famitinib 25 mg/d
Trial: 24939214
Drug: Famitinib 25
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famitinib 25 mg/d with elevated TSH
Trial: 24944232
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir (DTG) 50 mg plus abacavir/lamivudine (600/300 mg) once daily
Trial: 24944546
Drug: Acute sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute sodium citrate supplementation (0.5 g kg(-1) administered 120 min pre-trial)
Trial: 24944546
Drug: Chronic sodium
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic sodium citrate supplementation (0.1 g∙kg(-1) for three days and 0.3 g kg(-1) on the fourth day 120 min pre-trial)
Trial: 24944934
Drug: Oral anti-diabetic
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-diabetic drugs (OADs)
Trial: 24944934
Drug: Insulin (±OADs)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (±OADs)
Trial: 24944934
Drug: Barriers to
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers to insulin therapy
Trial: 24948692
Drug: Oral forodesine
RxNorm normalized name: Forodesine
DrugBank: Forodesine (DB06185)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral forodesine at a dose of 200 mg daily
Trial: 24949622
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavior therapy (ICBT) for 12 weeks with therapist support.
Trial: 28858443
Drug: Citalopram monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram monotherapy
Trial: 24950779
Drug: Flutamide (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (125 mg/day for 6 weeks)
Trial: 24950912
Drug: Prospective home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospective home monitoring based on daily assessment of FEV1 and electronic symptom score
Trial: 24952265
Drug: 10-week aerobic
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-week aerobic exercise program (cycling twice a week for an hour)
Trial: 24952730
Drug: Novel combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel combination therapies targeting AKT/PI3K pathways
Trial: 24952730
Drug: Sunitinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib and regorafenib (VEGFR targeting drugs)
Trial: 24952730
Drug: CTLA4 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTLA4 and PD-1/PD-L1 antibodies
Trial: 24953566
Drug: nab-paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel 100 mg/m² days 1 and 8, cisplatin 75 mg/m² day 1, 5-fluorouracil 1000 mg/m²/day for 96 hours days 1-4, every 3 weeks for three cycles
Trial: 24953566
Drug: Concurrent carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent carboplatin (AUC 1.5 weekly) with radiation therapy (70 Gy/35 fractions)
Trial: 24954791
Drug: Degarelix (240mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (240mg starting dose, then 80mg once a month for 6 months)
Trial: 24956535
Drug: RBP4 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBP4 levels in HGCS (51.44 ± 16.23 mg/L)
Trial: 24956535
Drug: Omentin-1 levels
RxNorm normalized name: benztropine mesylate 1 MG/ML [Cogentin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omentin-1 levels in HGCS (490.41 ± 172 ng/ml)
Trial: 24957163
Drug: CCRT (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT (two cycles of the DEP regimen every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk)
Trial: 24957163
Drug: CCRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT plus consolidation chemotherapy
Trial: 24957534
Drug: Mifepristone (200mg)
RxNorm normalized name: mifepristone 200 MG
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (200mg) followed by Misoprostol (800μg buccal)
Trial: 24958808
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of zoledronic acid
Trial: 24960544
Drug: Cholecalciferol (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (10,000 IU weekly)
Trial: 24961662
Drug: Simeprevir (TMC435)
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir (TMC435) 100 mg once daily with PEG IFN-α-2b/RBV
Trial: 24963043
Drug: Carfilzomib 56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib 56 mg/m2
Trial: 24963043
Drug: Carfilzomib 56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib 56 mg/m2 + Dexamethasone (20 mg)
Trial: 24963497
Drug: Low-dose decitabine-based
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine-based chemoimmunotherapy
Trial: 24964084
Drug: EV71-C4a vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71-C4a vaccine
Trial: 24964817
Drug: Initial altered
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial altered cardiac metabolism
Trial: 24965748
Drug: Orteronel 300
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orteronel 300 mg twice daily until PSA progression, metastases, or unacceptable toxicity.
Trial: 24965999
Drug: Unilateral laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral laparoscopic ovarian drilling with thermal doses adjusted to ovarian volume: median of 720J (IQR)
Trial: 24965999
Drug: Bilateral drilling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral drilling with fixed doses of 1200J
Trial: 24966411
Drug: Phytase added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytase added to maize porridge immediately before consumption or used for dephytinization during meal preparation
Trial: 24969506
Drug: Aspirin within
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin within 24 hours
Trial: 24969516
Drug: Doxycycline monohydrate,
RxNorm normalized name: Doxycycline Monohydrate, monohydrate 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline monohydrate, 50 mg/d for 24 months
Trial: 24969797
Drug: Postoperative hyperfractionated
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative hyperfractionated radiation therapy (36 Gy to craniospinal axis, 68 Gy to tumor region, 72 Gy to residual tumor, fractionated at 2 × 1 Gy per day 5 days per week) followed by maintenance chemotherapy (lomustine, cisplatin, and vincristine)
Trial: 24969797
Drug: Postoperative hyperfractionated
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative hyperfractionated radiation therapy followed by maintenance chemotherapy
Trial: 24970468
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H)
Trial: 24970686
Drug: 3% saline
RxNorm normalized name: dextrose 2.5%-0.3% saline (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% saline infusion
Trial: 24970773
Drug: Escitalopram, sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, sertraline, or extended-release venlafaxine (8-week course)
Trial: 24972362
Drug: Tranylcypromine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranylcypromine up to 60 mg/d
Trial: 24972362
Drug: Tranylcypromine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranylcypromine up to 120 mg/d
Trial: 24974232
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of loop diuretics (furosemide)
Trial: 24974232
Drug: Bolus treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus treatment of loop diuretics (furosemide)
Trial: 24975800
Drug: Mannitol bronchial
RxNorm normalized name: MANNITOL BRONCHIAL CHALLENGE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol bronchial challenge (PD15 < 635 mg)
Trial: 24975800
Drug: Methacholine bronchial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine bronchial challenge (PC20 < 16 mg/mL)
Trial: 24975800
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between log-transformed mannitol and methacholine response-dose ratios
Trial: 24975809
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg daily for a mean of 10.0 days (range: 2.0 to 39.0 days)
Trial: 24975809
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg daily
Trial: 24976801
Drug: Community psychiatry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community psychiatry program (including psychiatrist appointments, individual and group therapy, enhanced access to psychiatric medications) for 1 year
Trial: 24977639
Drug: Simulated effect-site
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated effect-site target of 3.2 μg/mL
Trial: 24978858
Drug: Oral antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidiabetic drugs (OAD)
Trial: 24979126
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available medical therapies (non-ESDS group)
Trial: 24980704
Drug: WHO criteria
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO criteria for GDM (fasting plasma glucose ≥ 7.0 mmol/L and/or 2-hour plasma glucose ≥ 7.8 mmol/L)
Trial: 24980704
Drug: Simplified IADPSG
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simplified IADPSG criteria (fasting glucose ≥ 5.1 mmol/L and/or 2-h plasma glucose ≥ 8.5 mmol/L)
Trial: 24982681
Drug: Transdermal 17β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β estradiol (TBE)
Trial: 24982681
Drug: Oral 17β
RxNorm normalized name: polyoxypropylene (17)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17β estradiol (OBE)
Trial: 24982681
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (OCEE)
Trial: 24983206
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of initial antibiotic treatment
Trial: 24986638
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment for 14 weeks
Trial: 24988120
Drug: NT-proBNP ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP ≥ 160 pg/mL
Trial: 24988120
Drug: Both TRV
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL
Trial: 24988476
Drug: Metformin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (oral medication)
Trial: 24990396
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg bid maintenance dose (MD)
Trial: 24990396
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg bid MD
Trial: 24990578
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with treatment interruption
Trial: 24990911
Drug: Influenza A(H1N1)
RxNorm normalized name: influenza A(H1N1)vac mv-sp2009 15 mcg/0.5 mL INTRAMUSC VIAL (ML)
DrugBank: Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) (DB14444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza A(H1N1) vaccine
Trial: 24991041
Drug: 1 mg/d
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/d of folic acid (Pregnant Women)
Trial: 24991041
Drug: 0 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/d of folic acid (Nonpregnant Women - NPW-0)
Trial: 24991041
Drug: 1 mg/d
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/d of folic acid (Nonpregnant Women - NPW-1)
Trial: 24991041
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d of folic acid (Nonpregnant Women - NPW-5)
Trial: 24992294
Drug: Atazanavir/ritonavir 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir 300/100 mg once daily with tenofovir
Trial: 24992294
Drug: Atazanavir/ritonavir 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir 300/100 mg once daily without tenofovir
Trial: 24992948
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of 0.75 g L-alanine-L-glutamine for 24 hours
Trial: 24992948
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of 0.75 g L-alanine-L-glutamine for 5 days
Trial: 24996961
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification intervention; details on dosage and duration not available.
Trial: 24997153
Drug: Deferasirox at
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox at a starting dose of 10 mg/kg/day for 52 weeks
Trial: 24997153
Drug: Deferasirox therapy
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox therapy continued
Trial: 24997153
Drug: Deferasirox therapy
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox therapy discontinued
Trial: 24997880
Drug: Oral cysteamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cysteamine bitartrate (60 mg/kg per day) and N-acetylcysteine (60 mg/kg per day)
Trial: 24997880
Drug: Oral cysteamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cysteamine bitartrate and N-acetylcysteine
Trial: 25001321
Drug: ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranibizumab (0.5 mg)
Trial: 25001321
Drug: bevacizumab (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bevacizumab (1.25 mg)
Trial: 25001321
Drug: aflibercept (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aflibercept (2.0 mg)